24 -30th April each year is the World Health Organisation World Immunization Week. To mark this occasion, NDM spoke to Professor Simon Draper, a MRC Career Development Fellow based at the Jenner Institute, about making vaccines more effective.
Simon Draper: A vaccine relies on the remarkable ability of the immune system to recognise what it has seen before – we call this process immunological memory.
The last week of April each year is the World Health Organisation Immunization Week. Clinical trials are an essential part of vaccine development and The Jenner Institute has been involved in a fast-tracked Ebola Phase I clinical trial in response to the Ebola outbreak in West Africa.
NDM spoke to Dr Katie Ewer, a Senior Immunologist involved in this trial, about the need for an Ebola vaccine and what the next steps are.
Last year to mark World Tuberculosis Day NDM spoke to Professor Helen McShane to find out more about her research developing an improved TB vaccine. NDM spoke to her again to find out if there have been any developments in the last year.
The University of Oxford is delighted to announce that the first collaborative research projects to be agreed by the University under the Pfizer Rare Disease Consortium have been signed.
The University of Oxford and its Clinical BioManufacturing Facility have approached MHRA in order to receive feedback, guidance and support in the development and manufacture of a candidate vaccine for treatment of malaria that has seen them explore an innovative approach to viral vectors using a chimpanzee virus.
Reuters: As West Africa's devastating Ebola outbreak begins to dwindle, scientists are looking beyond the endgame at the kind of next-generation vaccines needed for a vital stockpile to hit another epidemic hard and fast.
The Guardian: The trial conducted at Oxford University paves the way for the vaccine, jointly developed by GlaxoSmithKline (GSK) and the US National Institutes of Health (NIH), to be further tested on patients in west Africa.
BBC: Sixty healthy volunteers were immunised at the University of Oxford's Jenner Institute. The findings, published in the New England Journal of Medicine, show the vaccine generated an immune response against Ebola. But it is not clear whether the vaccine will offer protection against the disease.
Reuters: First results from a human trial of an Ebola vaccine from GlaxoSmithKline show it is safe and generates an immune response, scientists said on Wednesday, but larger trials are needed to see if it protects and if a booster is needed.
Press release: The first results from the Ebola vaccine trial carried out by the Jenner Institute found that the vaccine has an acceptable safety profile at the doses tested, and is able to generate an immune response. The paper published in the New England Journal of Medicine reports safety data and immune responses for the volunteers for 28 days after immunisation.
If you have news or events that you would like to be added to this website, please email us details. If possible, please include a picture and links to further information.